Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.
The Accreditation Sub-Committee of the EBMT regularly publishes special reports on current practice of haemopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders. Major changes have occurred since the last report in 1998. Haemopoietic stem cell transplantation today includes allogeneic and autologous stem cells derived from bone marrow, peripheral blood and cord blood. With reduced intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous, and solid tumours for allogeneic transplants. Other indications, such as autologous transplantation for breast cancer have been challenged. An updated report with revised tables and operating definitions is presented here.
Urbano-Ispizua
A
A
Dept of Hematology, Hospital Clinic, Barcelona, Spain.
Schmitz
N
N
de Witte
T
T
Frassoni
F
F
Rosti
G
G
Schrezenmeier
H
H
Gluckman
E
E
Friedrich
W
W
Cordonnier
C
C
Socie
G
G
Tyndall
A
A
Niethammer
D
D
Ljungman
P
P
Gratwohl
A
A
Apperley
J
J
Niederwieser
D
D
Bacigalupo
A
A
D000328:Adult; D002648:Child; D002985:Clinical Protocols; D005060:Europe; D006402:Hematologic Diseases / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000639:trends*; D006801:Humans; D007154:Immune System Diseases / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D012955:Societies, Medical; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous